Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Receivables (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Receivables for 4 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 9.28% to $21.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $80.7 million, a 49.85% increase, with the full-year FY2025 number at $80.7 million, up 49.85% from a year prior.
  • Change in Receivables was $21.2 million for Q4 2025 at Madrigal Pharmaceuticals, down from $34.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $34.1 million in Q3 2025 to a low of $6.9 million in Q2 2024.